CTX101

CTX101 is an **allogeneic CRISPR-based CAR-T cell therapy** designed to target and eliminate malignant cells expressing CD19, a surface antigen widely present in B-cell derived cancers, such as certain lymphomas and leukemias. Unlike autologous CAR-T therapies, CTX101 is derived from healthy donor T-cells, which are genetically modified ex vivo using CRISPR/Cas9 technology to improve persistence, reduce the risk of graft-versus-host disease, and provide a broadened off-the-shelf cell therapy option. It is being developed primarily for the treatment of **CD19-positive hematologic malignancies**, aiming to overcome limitations of patient-derived cell therapies such as production time and variability. The drug was developed by **CRISPR Therapeutics**, with manufacturing partnerships involving MaSTherCell[5][8][9][11].

Brand names

CTX101CTX-101CTX 101

Other names

CTX101CTX-101CTX 101